Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have received an average rating of "Buy" from the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $31.86.

Several research analysts recently issued reports on BCAX shares. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target for the company in a research report on Friday, May 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently modified their holdings of BCAX. Red Tree Management LLC acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $55,230,000. Vestal Point Capital LP increased its holdings in shares of Bicara Therapeutics by 290.0% during the first quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock worth $36,080,000 after buying an additional 2,058,975 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Bicara Therapeutics by 171.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after buying an additional 1,375,265 shares in the last quarter. Deep Track Capital LP increased its holdings in shares of Bicara Therapeutics by 151.0% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock worth $34,840,000 after buying an additional 1,203,148 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Bicara Therapeutics by 1,457.9% during the fourth quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock valued at $18,997,000 after purchasing an additional 1,020,528 shares during the last quarter.

Bicara Therapeutics Stock Down 1.2%

Shares of BCAX traded down $0.11 during trading hours on Thursday, reaching $9.32. 581,796 shares of the company traded hands, compared to its average volume of 584,125. The stock's fifty day moving average is $12.34 and its 200 day moving average is $13.48. Bicara Therapeutics has a 1-year low of $7.80 and a 1-year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). On average, equities research analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.